Key facts
- It has raised $9.9M; the latest was Early Stage VC ($7.4M) in Jul 2025.
- Notable investors include Angel to Venture.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Primo Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Primo Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Primo Biotechnology
Operator of a molecular imaging platform intended to provide an accurate diagnosis of cancer. The company's platform specializes in non-invasive radiopharmaceutical imaging technology to detect early-stage colorectal cancer, esophageal cancer, and lung adenocarcinoma, enabling doctors to make informed decisions, personalize and expedite cancer care.
- Sector
- Healthcare
- HQ
- Taipei City, Taiwan
- Founded
- 2021
- Website
- primobt.com/
- Ownership
- Privately Held (backing)
Primo Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primo Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primo Biotechnology in its N-PORT filings yet. We sweep new filings monthly.